Pro Medicus H1 profit soars on global expansion

Leading health imaging innovator Pro Medicus (ASX:PME) has delivered a stellar half-year performance for the period ended December 2025, underscored by revenue growth and a massive surge in reported net profit.

The company announced a revenue increase of 28.4% to $124.8 million, while underlying profit before tax rose nearly 30% to $90.7 million.

Reported net profit after tax skyrocketed 230.9% to $171.2 million, a figure bolstered by $149.1 million in unrealised gains from a strategic $10 million investment in 4D Medical (ASX:4DS).

Pro Medicus continues to demonstrate best-in-class efficiency, with underlying EBIT margins expanding to 73%.

Despite aggressive capital management—including increased dividends and two share buybacks—the company's balance sheet remains fortress-like.

It closed the half-year with $221.8 million in cash and financial assets and maintains a coveted debt-free status.

Shareholders are set to benefit directly from this performance, with the board declaring a fully franked interim dividend of 32 cents per share.

The reporting period was also defined by a rapid expansion of the company's global footprint.

Pro Medicus secured seven major new contracts, highlighted by a landmark 10-year, $170 million deal with the University of Colorado.